Bryan Garnier - HYDROGENPRO ASA (HYPRO) HydrogenPro: Q1 results

Report

Bryan Garnier

Mahaut Arnaud ...

Paul de Froment
Thomas Mordelle

HydrogenPro: Q1 results

HydrogenPro has reported Q1 2025 results this morning confirming challenging dynamics due to lacking and postponed investment decisions for green hydrogen production. Revenue came in at NOK22m in Q1 2025 (vs FY25 cons. at NOK469m), mostly derived from the SALCOS project with Andritz in Germany, for

15/05/2025 1 EN

Underlying

HYDROGENPRO ASA

See profile

NO0010892359 Norway

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Mahaut Arnaud

Paul de Froment

Thomas Mordelle

Other Reports on these Companies

Bryan Garnier

HydrogenPro: poor FY24 results, waiting for new orders

Today HydrogenPro reported FY24 results with revenues at NOK196m (-11% vs cons. at NOK221m, -66% YoY). Gross margin stood at 25% (+3.7ppt YoY), driven by ongoing developments for the Salzgitter Flachstahl project and impacted by one-off ACES costs during the year. While HydrogenPro regularly delive

February 25, 2025 February 25, 2025 1 EN

Bryan Garnier

HydrogenPro: up to NOK140m in equity financing from Andritz, MHI and Longi Hydrogen

HydrogenPro announced yesterday that it has secured (i) NOK70m in new equity from its existing strategic investors Andritz and Misubishi Heavy Industries (MHI) through a private placement, as well as (ii) an investment agreement for a conditional NOK70m equity investment and a cooperation agreement

December 24, 2024 December 24, 2024 1 EN

Camurus Q1: Beat on profitability, Buvidal/Brixadi momentum preserved

Camurus reported its Q1'25 results, with topline revenues of SEK558m (c. -6% vs css, primarily due to FX), and a beat on profitability with PBT coming in at SEK254m (c. +20% vs css). Buvidal maintained its growth momentum in Q1 with 3,000 new patients on treatment (vs. 4,000 in Q4, but consistent w

5h / 34m 5h / 34m 1 EN

Oscar Haffen Lamm

Oscar Haffen Lamm

BioInvent: BI-1808 meets bar in CTCL; BI-1206 in NHL slightly below threshold

Yesterday afternoon, the company released new data from two programs: BI-1808 in CTCL and BI-1206 (triple combo with AZ's Calquence) in NHL. For BI-1808 in CTCL, the dataset now includes 8 patients (up from 4 previously), showing 1 new complete response (CR), 3 partial responses (PR), and 4 stable

5h / 46m 5h / 46m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

HydrogenPro: Q1 results

HydrogenPro: poor FY24 results, waiting for new orders

HydrogenPro: up to NOK140m in equity financing from Andritz, MHI and Longi Hydrogen

Camurus Q1: Beat on profitability, Buvidal/Brixadi momentum preserved

BioInvent: BI-1808 meets bar in CTCL; BI-1206 in NHL slightly below threshold

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe